Comparison of intravitreal ranibizumab and bevacizumab treatment for retinopathy of prematurity

Related authors

• Muhammet Kazim Erol
• Deniz Turgut Coban
• Esin Sogutlu Sari
• Ahmet Burak Bilgin
• Berna Dogan
• Ozdemir Ozdemir
• Zuhal Ozen Tunay

Related articles

• Is there a relationship between the first-day results of anti-VEGF therapy for macular edema due to vascular diseases and longterm outcomes?
• Evaluation of contrast sensitivity in non-high-risk proliferative diabetic retinopathy treated with panretinal photocoagulation with and without intravitreal injections of ranibizumab
• Age-related macular degeneration: a review of current therapies and new treatments
• Three versus five intravitreal aflibercept injections as the initial loading phase in the treatment of diabetic macular edema: one-year results
• Profile of patients treated with intravitreal antiangiogenics in a Brazilian public service with high level of complexity
• Should intravitreal dexamethasone implant in refractory diabetic macular edema be used as an adjuvant therapy or switch therapy?
• Switch to aflibercept in the treatment of neovascular age-related macular degeneration: 30-month results
• Changes in the ganglion cell complex thickness after anti-VEGF treatment for diabetic macular edema
• Prospective evaluation of the effectiveness of combined treatment of macular edema secondary to retinal vein occlusion with intravitreal bevacizumab and dexamethasone implants
• Retinopathy of prematurity: Accuracy of ROPScore and WINROP algorithms in a Brazilian population

Click here to search